ImmuCell Number Of Shares Shorted vs. Price To Earning

ICCC Stock  USD 3.69  0.03  0.82%   
Taking into consideration ImmuCell's profitability measurements, ImmuCell may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess ImmuCell's ability to earn profits and add value for shareholders.
For ImmuCell profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ImmuCell to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ImmuCell utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ImmuCell's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ImmuCell over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

ImmuCell Price To Earning vs. Number Of Shares Shorted Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining ImmuCell's current stock value. Our valuation model uses many indicators to compare ImmuCell value to that of its competitors to determine the firm's financial worth.
ImmuCell is rated below average in number of shares shorted category among its peers. It is currently regarded as number one stock in price to earning category among its peers reporting about  0.05  of Price To Earning per Number Of Shares Shorted. The ratio of Number Of Shares Shorted to Price To Earning for ImmuCell is roughly  20.56 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmuCell's earnings, one of the primary drivers of an investment's value.

ImmuCell Price To Earning vs. Number Of Shares Shorted

Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

ImmuCell

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
4.01 K
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

ImmuCell

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
195.00 X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

ImmuCell Price To Earning Comparison

ImmuCell is currently under evaluation in price to earning category among its peers.

ImmuCell Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in ImmuCell, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ImmuCell will eventually generate negative long term returns. The profitability progress is the general direction of ImmuCell's change in net profit over the period of time. It can combine multiple indicators of ImmuCell, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Immucell operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 64 people.

ImmuCell Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on ImmuCell. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ImmuCell position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ImmuCell's important profitability drivers and their relationship over time.

Use ImmuCell in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmuCell position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmuCell will appreciate offsetting losses from the drop in the long position's value.

ImmuCell Pair Trading

ImmuCell Pair Trading Analysis

The ability to find closely correlated positions to ImmuCell could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ImmuCell when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ImmuCell - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ImmuCell to buy it.
The correlation of ImmuCell is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ImmuCell moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ImmuCell moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ImmuCell can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your ImmuCell position

In addition to having ImmuCell in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Recycling Thematic Idea Now

Recycling
Recycling Theme
West management companies as well as entities specializing in pollution control and recycling. The Recycling theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recycling Theme or any other thematic opportunities.
View All  Next Launch
When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:
Check out Risk vs Return Analysis.
For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
To fully project ImmuCell's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ImmuCell at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ImmuCell's income statement, its balance sheet, and the statement of cash flows.
Potential ImmuCell investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although ImmuCell investors may work on each financial statement separately, they are all related. The changes in ImmuCell's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ImmuCell's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.